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showed normal lactate (mean 0.89, p < 0.02); mean PA pressures
reduced to 20 mmHg (p < 0.05) within 36 h. There was complete
recovery in all. No recurrences observed in average 7months (range
4–24 months) follow-up.
Conclusion: Early clinical suspicion of cardiac beriberi is extremely
important in infants with low SE strata presenting with unex-
plained CHF and severe PAH.
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Introduction: Congenital bicuspid aortic valve is themost common
congenital anomaly incardiovascular systemaccounting for1–2%of
the population, more common inmen. Restrictive cardiomyopathy
is a heterogenous group of diseases characterized by a nondilated
left ventricle, often with a well preserved ejection fraction.
Case: A 52-year-old male, nonhypertensive, diabetic came with
complaints of shortness of breath, abdominal distention, pedal
edema. On examination, he had raised JVP, pulse 54/min, BP – 100/
70 mmHg. On CVS examination, there was S1, S2, lungs b/l creps
were heard. His Hb – 10.5 g/dl,WBC counts were normal. Renal
parameters were within normal limits. Liver function tests – nor-
mal. Viral screening – negative. USG abdomen – gross ascites, b/l
pleural effusion, liver size normal. Chest X-ray – cardiomegaly, b/l
pleural effusion. ECG – idioventricular rhythm, low voltage com-
plexes. Echo showed biatrial enlargement with normal sized ven-
tricles and normal systolic function with grade III diastolic
dysfunction. There was bicuspid aortic valve with calciﬁcation,
antero-posteriororientationofcommissuresandpositiveeccentricity
index. There wasmoderate aortic stenosis andmild aortic regurgita-
tion. Due to disparity between the echo ﬁndings and the clinical
situation, restrictivecardiomyopathywassuspectedandaabdominal
fat pad biopsy was done with Congo red staining and subjected to
polar microscopy. The biopsy was positive for amyloidosis.
Discussion: Amyloid deposition in heart is a common occurrence
in systemic amyloidosis (50% occurrence). Fine needle aspiration
of abdominal fat pad is minimally invasive, convenient, safe, eco-
nomical, simple procedure for the tissue diagnosis of AL. It has
sensitivity of 52–88% and speciﬁcity >95%, equal to or better than
rectal biopsies with Congo red staining. Congestive heart failure is
the presenting feature in restrictive cardiomyopathywith amedian
survival is <6 months after onset of heart failure. Gofﬁn et al.
reported the termdystrophic valvular amyloidosis' in a patientwith
a calciﬁc bicuspid aortic valve subjected to aortic valve replacement
on biopsy. Association of a biscupid aortic valve with RCMP is rare
and to the best of our knowledge it is the second case report.
Clinical implications: Association of bicuspid aortic valve with
restrictive cardiomyopathy is rare.
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Background: Heart failure as a chronic progressive disorder of all
heart failure patients eventually progress to a refractory stage
characterized by worsening renal function and resistance to diure-
tic therapy with attending severe edema. A logical treatment for
this ‘‘cardiorenal syndrome’’ is the use of dialysis, which is
efﬁcient in treating both the hypervolemia and azotemia of
refractory heart failure. Peritoneal ultraﬁltration is associated
with preservation of residual renal function, gentle continuous
ultraﬁltration, hemodynamic stability, sodium sieving with
maintenance of normonatremia and perhaps less inﬂammation
than hemodialysis.
Methods: The study was conducted prospectively on cohort of
patients for two years patients with NYHA functional class III/
IV; refractory heart failure with ejection fraction (EF) <45%. And
one out of two criteria (i) persistent dyselectrolytemia (hypona-
tremia or hypokalemia); (ii) at least one previous hospitaliza-
tions for acute heart failure in previous 3 month, were followed
for a median of 3 months after the catheter implantation. To
measure the success of ultraﬁltration, the endpoint will be
deﬁned by changes that occurred in study variables pre- and
post-ultraﬁltration at 3 months. NYHA class, 6 MIN WALK TEST,
days of rehospitalisation or unscheduled visit or admission,
hemoglobin, serum creatinine, eGFR, sodium, NTproBNP. Echo-
cardiographic parameters before and after ultraﬁltration at 3
months.
A total of 19 study subjects were studied, most of them 17 (89.4%)
were male while only 02 (10.6%) were female. We found sig-
niﬁcant increase in ejection fraction measured by Simpson
method. EF before the treatment was (35.4  6.6), (43.1  13.8)
with mean difference (7.64  10.4) at the end of 3 months. After
ultraﬁltration, duration of hospital stay, hospitalization rate and
cases in NYHA class III and IV highly signiﬁcantly reduced
( p < 0.0001), while other parameters like Hb (g%) and EF showed
signiﬁcant increase ( p < 0.0001) after ultraﬁltration. After ultra-
ﬁltration, RVSP signiﬁcantly reduced ( p < 0.001), was marker for
ﬂuid overload state; physical activity index (6MWT) and NYHA
class improved signiﬁcantly in our study over the period of
3 months p < 0.001 and p < 0.01 respectively. Signiﬁcant
reduction was observed in level of NTproBNP. There was
improvement in serum sodium level ( p < 0.05) after ultraﬁltra-
tion. We noticed there was signiﬁcant increase in the hemoglo-
bin (g%).
Conclusion: This preliminary study indicates that ultraﬁltration is
a feasible alternative for the treatment of symptomatic patients
with advanced CHF, persistent ﬂuid overload despite loop diuretic
therapy excluding patient with ESRD and echocardiography is a
good tool to assess effect of ultraﬁltration.
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Aim: Global hypokinesia of left ventricle (GHLV) is uncommon in
ICMP that delays the proper treatment because of confusion
with DCMP as the closest differential diagnosis. Here author
has tried to evaluate the role of coronary angiogram in unex-
plained dilated and signiﬁcant GHLV of with no prior documen-
tation of CAD.
Methods: This was the prospective observational study carried at a
single centre serving the large number of population in North-East
India, which included 30 patients during the period March-2015 to
August-2015 (period of four months). The study group consists of
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patients having dilated and GHLV with signiﬁcant left ventricu-
lar dysfunction without documented CAD before. EF% was com-
puted by Simpson's method. Epidemiological data and details of
risk factors were studied. CAG was done in all patients. Both
femoral and radial access taken. Treatment plan was modiﬁed
after CAG and viability study results depending upon the
CAD status. Follow up results at the end of four month were
analyzed.
Results: Out of 30 patients with dilated and GHLV with severe left
ventricular dysfunction, majority of patient (13) belong to age
group 40–49 years (45%) 21 patients had normal CAG (60%) and
5 patients had signiﬁcant CAD (20%). A total of 3 patients under-
went CABG and 1 patient had undergone angioplasty. Only
2 patients developed mild renal dysfunction and improved on
follow up.
Conclusions: CAD was seen in 20% of patients with dilated and
GHLV. CAG is safe even up to LVEF of as low as 20%. The triad of low
EF, signiﬁcant CAD and viable myocardium provides favorable
prognosis. Mild CAD needs optimized medication.
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Angiotensin-converting enzyme (ACE) and beta blockers are the drugs
which decrease mortality and increase longevity in patients with
heart failure.
Aims and objects: The incidence of heart failure in India is increas-
ing and it affects relatively younger patients. Present study aims to
identify the limiting factors in giving optimal medical manage-
ment in patients with heart failure.
Subjects and methods: This prospective descriptive study was
done at Kerala Institute of Medical Sciences Trivandrum, over a
2 years period from 1st June 2012. Three hundred consecutive
patients with NYHA class 3 or 4 with various etiology of heart
failure were identiﬁed and then all treated patients were analyzed.
Results: Of the 300 patients, 69% (n – 208) were males and 31% (n –
92) were females. Below 70 years there was male predominance of
heart failure but after the age of 70 there was female predomi-
nance.
In our study 94.6% (n = 284) of patients received loop diuretics,
mainly frusemide 55.6% (n – 167) and torsemide 39% (n – 117).
Thiazide diuretics were used infrequently. Metalazonewas used in
8% (n – 24) of patients with loop diuretics when renal failure was
present. Potassium sparing diuretics, spiranolactone were used in
45.6% (n – 137) of patients and eplerenone in 9.3% (n – 28). Only 34%
(n – 104) of patients received ACE or ARB, of which 23.6% (n – 71)
were on ACE inhibitors). ARBs were used by 11% (n – 33) of patients
who were intolerant to ACE inhibitors, mainly due to dry cough.
ACE inhibitors could not be used due to hypotension in 34% (n –
103) of patients and renal failure in 31% (n – 93) of patients. Beta
blockers could be used only in 43% (n – 130) of patients because of
hypotension in 60% (n – 102), bronchial asthma in 20% (34), bra-
dycardia in 15% (25), and chronic obstructive pulmonary disease in
5% (n – 9) of patients.
Conclusion: The mainstay in the management in heart failure
today is ACE inhibitors and beta blockers. We found limitations
in using ACE inhibitors due to comorbidities like renal failure
and hypotension. Beta blockers could be used only in 43% of
patients. Even when the cardiac failure was long standing per-
sistence of contraindications limits the use of ACE/ARB and beta
blockers.
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Background: Patients of STEMI withMVD are at higher risk of heart
failure, cardiogenic shock and associated with 2 time's higher
mortality during hospitalization. The aim of the study was to
compare the outcome of culprit vessel only PCI and multivessel
PCI during the index procedure or staged in patients with STEMI
and MVD.
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